Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;15(2):423-41, vii-x.
doi: 10.1016/j.cld.2011.03.002.

Systemic therapy in hepatocellular carcinoma

Stephen H Wrzesinski  1 , Tamar H Taddei, Mario Strazzabosco
Affiliations
Review

Systemic therapy in hepatocellular carcinoma

Stephen H Wrzesinski et al. Clin Liver Dis. 2011 May.

Abstract

Many potential systemic therapies are being investigated for the treatment of hepatocellular carcinoma (HCC). The incidence of this malignancy is rising sharply and the vast majority of patients present at advanced stages. Although the earlier dismal results with cytotoxic chemotherapies made way for the development of locoregional therapies that provided improved overall survival, truly personalized therapy will require the selection of phenotypically similar stages of disease and populations, an understanding of the complex molecular and genetic pathways leading to HCC, and a keen understanding of the pathobiology of cirrhosis. Only then will we understand how to offer a particular patient at a specific stage of disease the appropriate therapy to truly prolong survival.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summary of converging molecular pathways in HCC inhibited by targeted agents. Antibodies listed in italics and small molecular inhibitors in shaded rectangles. EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; PDK, phosphate-dependent kinase; PTEN, phosphatase and tensin homolog deleted in chromosomes 10; mTOR, mammalian target of rapamycin; MEK, mitogen-activated protein kinase kinase; ERK, extracellular related kinase.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5–S16. - PubMed
    1. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200. - PubMed
    1. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complication rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47(1):82–89. - PubMed
    1. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373(9664):614–616. - PubMed
    1. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S179–S188. - PubMed

Publication types

MeSH terms

Substances